DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Active, not recruiting

Conditions: Waldenstrom's Macroglobulinemia
Multiple Myeloma
Smoldering Multiple Myeloma
Lymphoblastic Lymphoma

First Posted Date: 2010-08-09

Last Posted Date: 2024-08-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 656

Registration Number: NCT01177527

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Methylphenidate for Cancer-Related Fatigue

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: methylphenidate
Other: Placebo

First Posted Date: 2010-07-19

Last Posted Date: 2019-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01164956

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Everolimus
Drug: Rituximab
Drug: Bortezomib

First Posted Date: 2010-05-18

Last Posted Date: 2021-04-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT01125293

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

NIR-Guided Sentinel Lymph Node Mapping in Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: ICG Intervention

First Posted Date: 2010-05-12

Last Posted Date: 2017-02-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01121718

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Lexiscan

First Posted Date: 2010-03-11

Last Posted Date: 2014-03-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 39

Registration Number: NCT01085201

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Childrens Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 4 locations

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia

Interventions: Drug: pyrimethamine

First Posted Date: 2010-02-10

Last Posted Date: 2023-02-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01066663

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Panobinostat (LBH589) in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma
Malignant Melanoma

Interventions: Drug: LBH589

First Posted Date: 2010-02-09

Last Posted Date: 2017-03-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT01065467

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Gastrointestinal Cancer

Interventions: Drug: Everolimus
Drug: Tivozanib

First Posted Date: 2010-01-29

Last Posted Date: 2017-04-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 56

Registration Number: NCT01058655

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Radiation: Intensity modulated radiotherapy
Drug: RAD001
Drug: cisplatin

First Posted Date: 2010-01-28

Last Posted Date: 2013-02-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01058408

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Tumor
Neuroendocrine Tumor
Carcinoid Tumor

Interventions: Drug: AMG 479

First Posted Date: 2009-12-02

Last Posted Date: 2018-03-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT01024387

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy